Hospital-acquired pneumonia overview

Jump to navigation Jump to search

Pneumonia Main Page

Hospital-acquired pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hospital-Acquired Pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Diagnostic Algorithm

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hospital-acquired pneumonia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hospital-acquired pneumonia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hospital-acquired pneumonia overview

CDC onHospital-acquired pneumonia overview

Hospital-acquired pneumonia overview in the news

Blogs on Hospital-acquired pneumonia overview

Directions to Hospitals Treating Hospital-acquired pneumonia

Risk calculators and risk factors for Hospital-acquired pneumonia overview

Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. ; Philip Marcus, M.D., M.P.H.

Overview

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.[1][2] HAP is the second most common nosocomial infection (after urinary tract infections ) and accounts for 15–20% of the total.[1][2][3] It is the most common cause of death among nosocomial infections and is the primary cause of death in intensive care units.[1][3] HAP typically lengthens a hospital stay by 1–2 weeks.[1][3]

Pathophysiology

Most nosocomial respiratory infections are caused by so-called skorvatch microaspiration of upper airway secretions, through inapparent aspiration, into the lower respiratory tract. Also, "macroaspirations" of esophageal or gastric material is known to result in HAP. Since it results from aspiration either type is called aspiration pneumonia. Although gram-negative bacilli are a common cause they are rarely found in the respiratory tract of people without pneumonia, which has led to speculation of the mouth and throat as origin of the infection.

Causes

The majority of cases related to various gram-negative bacilli (52%) and S. aureus (19%). Others are Haemophilusspp. (5%). In the ICU results were S. aureus(17.4%), P. aeruginosa (17.4%), Klebsiella pneumoniae andEnterobacter spp. (18.1%), and Haemophilus influenzae (4.9%). Viruses -influenza and respiratory syncytial virus and, in the immunocompromised host, cytomegalovirus- cause 10-20% of infections.

Differentiating Hospital-Acquired Pneumonia From Other Diseases

Hospital-acquired pneumonia must be differentiated from other conditions that cause fever, cough, chest pain, tachycardia, and leukocytosis in hospitalized patients, such as atelectasis, congestive heart failure, pulmonary embolism, aspiration pneumonitis, among others. [4][5]

Epidemiology and Demographics

The epidemiology of health-care-associated pneumonia varies considerably according to the type of health-care setting. Nosocomial pneumonia has been the second most common hospital-associated infection after that of the urinary tract. The primary risk factor for the development of hospital-associated bacterial pneumonia is mechanical ventilation. In long-term care facilities such as nursing homes, pneumonia is the first or second most common infection (after those of the urinary tract) acquired by patients, and accounts for 13-48% of all nursing home-associated infections. [6]

Risk Factors

Among the factors contributing to contracting HAP are mechanical ventilation (ventilator-associated pneumonia), old age, decreased filtration of inspired air, intrinsic respiratory, neurologic, or other disease states that result in respiratory tract obstruction, trauma, (abdominal) surgery, medications, diminished lung volumes, or decreased clearance of secretions may diminish the defenses of the lung. Also poor hand-washing and inadequate disinfection of respiratory devicescauses cross-infection and is an important factor.

Natural History, Complications, and Prognosis

The natural history of HAP depends on many factors and occurs 48 hours or more after hospitalization. Complications include sepsis, respiratory failure, pleural effusion, empyema, and lung abscess. Healthcare-associated pneumonia seems to have fatality rates similar to hospital-acquired pneumonia, worse than community-acquired pneumonia but less severe than pneumonia in ventilated patients. Besides clinical markers like tachypnea (fast breathing) or a high white cell count (leukocytosis), the prognosis seems to be influenced by the underlying associated diseases (comorbidities) and functional capacities.[7][8][9] Many patients have a decreased health condition after the episode.[10]

Diagnosis

Diagnostic Criteria

In hospitalised patient who develop respiratory symptoms and fever one should consider the diagnosis. The likelyhood increases when upon investigation symptoms are found of respiratory insufficiency, purulent secretions, newly developed infiltrate on the chest X-Ray, and increasing leucocyte count. If pneumonia is suspected material from sputum or tracheal aspirates are sent to the microbiology department for cultures. In case ofpleural effusion thoracentesis is performed for examination of pleural fluid. In suspected ventilator-associated pneumonia it has been suggested that bronchoscopy(BAL) is necessary because of the known risks surrounding clinical diagnoses.

History and Symptoms

People with pneumonia often have a productive cough, fevershaking chills, shortness of breath, pleuritic chest pain, hemoptysis, headaches, sweaty, and clammy skin. Other possible symptoms are loss of appetite, fatigue, cyanosis, nausea, vomiting, mood swings, and joint pains or muscle aches. In elderly people manifestations of pneumonia may not be typical. They may develop a new or worsening confusion or may experience unsteadiness, leading to falls. Infants with pneumonia may have many of the symptoms above, but in many cases they are simply sleepy or have a decreased appetite. In VAP, often no history is available in patients with ventilator-associated pneumonia as they are often sedated and are rarely able to communicate.

Physical Examination

Physical examination is important in diagnosing hospital-acquired pneumonia, finding include fever, tachypnea, rhonchi, crackles and wheezes. For ventilator-associated pneumonia, a deterioration in ventilator parameters such as, tachypnea, decreased tidal volume, increased minute ventilation, or decreased oxygen saturation could be the first indicators of a new onset ventilator-associated pneumonia.[11]

Laboratory Findings

Current guidelines recommend a combination of chest X-ray, laboratory data as well as clinical judgment in diagnosis and management of community acquired pneumonia. Laboratory tests include CBC, metabolic panel, sputum gram-stain and culture, serology for mycoplasma, chlamydia, and legionella. Additional test include bronchial samples and HIV testing for special conditions.

Chest X-ray

An important test for making a diagnosis of pneumonia is a chest x-ray. Chest x-rays can reveal areas of opacity (seen as white) which represent consolidation, pleural effusion, air bronchogram and/or cavitations. Pneumonia is not always seen on x-rays, either because the disease is only in its initial stages, or because it involves a part of the lung not easily seen by x-ray.

Treatment

Medical Therapy

The medical regimen in patients with hospital-acquired pneumonia will depend on the risk factors and the likelihood of drug resistance pathogens. For patients with no risk factors for MDR pathogens, the regimen consists of one antibiotic medication, usually ceftriaxone or a fluoroquinolone. For patients with risk of MDR pathogens, a three drug combination regimen is preferred; which includes an antipseudomonal cephalosporin or carbapenem plus a fluoroquinolone plus linezolid or vancomycin (for MRSA coverage).

Prevention

The prevention for HAP includes education of health-care workers about the epidemiology and infection-control procedures, and involve the workers in the implementation of interventions to prevent HAP by using performance-improvement tools and technique. Disinfection and maintenance of equipment and devices, as well as preventive measures of person to person transmission, are part of the preventive recommendations given by the CDC for HAP.

Cost-Effectiveness of Therapy

Linezolid was compared to vancomycin for the treatment of VAP, and showed cost-effectiveness as an alternative to vancomycin treatment as it had a higher cure rate and prices per treatment were similar.[12][13] One study reported that oropharingeal decontamination decreased the incidence of ventilator-associated pneumonia from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500. [14]

References

  1. 1.0 1.1 1.2 1.3 Mandell's Principles and Practices of Infection Diseases 6th Edition (2004) by Gerald L. Mandell MD, MACP, John E. Bennett MD, Raphael Dolin MD, ISBN 0-443-06643-4 · Hardback · 4016 Pages Churchill Livingstone
  2. 2.0 2.1 The Oxford Textbook of Medicine Edited by David A. Warrell, Timothy M. Cox and John D. Firth with Edward J. Benz, Fourth Edition (2003), Oxford University Press, ISBN 0-19-262922-0
  3. 3.0 3.1 3.2 Harrison's Principles of Internal Medicine 16th Edition, The McGraw-Hill Companies, ISBN 0-07-140235-7
  4. Koenig SM, Truwit JD (2006). "Ventilator-associated pneumonia: diagnosis, treatment, and prevention". Clin Microbiol Rev. 19 (4): 637–57. doi:10.1128/CMR.00051-05. PMC 1592694. PMID 17041138.
  5. "Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia". American Journal of Respiratory and Critical Care Medicine. 171 (4): 388–416. 2005. doi:10.1164/rccm.200405-644ST. ISSN 1073-449X.
  6. "CDC GUIDELINES FOR PREVENTING HEALTH-CARE-ASSOCIATED PNEUMONIA, 2003" (PDF).
  7. Mehr DR, Zweig SC, Kruse RL; et al. (October 1998). "Mortality from lower respiratory infection in nursing home residents. A pilot prospective community-based study". J Fam Pract. 47 (4): 298–304. PMID 9789516.
  8. Mehr DR, Binder EF, Kruse RL; et al. (November 2001). "Predicting mortality in nursing home residents with lower respiratory tract infection: The Missouri LRI Study". JAMA. 286 (19): 2427–36. doi:10.1001/jama.286.19.2427. PMID 11712938.
  9. Naughton BJ, Mylotte JM, Tayara A (October 2000). "Outcome of nursing home-acquired pneumonia: derivation and application of a practical model to predict 30 day mortality". J Am Geriatr Soc. 48 (10): 1292–9. PMID 11037018.
  10. Fried TR, Gillick MR, Lipsitz LA (March 1997). "Short-term functional outcomes of long-term care residents with pneumonia treated with and without hospital transfer". J Am Geriatr Soc. 45 (3): 302–6. PMID 9063275.
  11. Koenig, S. M.; Truwit, J. D. (2006). "Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention". Clinical Microbiology Reviews. 19 (4): 637–657. doi:10.1128/CMR.00051-05. ISSN 0893-8512.
  12. Shorr AF, Susla GM, Kollef MH (2004). "Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin". Crit Care Med. 32 (1): 137–43. doi:10.1097/01.CCM.0000104110.74657.25. PMID 14707572.
  13. De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S; et al. (2009). "Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany". Infection. 37 (2): 123–32. doi:10.1007/s15010-008-8046-7. PMID 19277465.
  14. van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ (2004). "Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units". Crit Care Med. 32 (1): 126–30. doi:10.1097/01.CCM.0000104111.61317.4B. PMID 14707570.

Template:WH Template:WS